New stock news | Shanghai Shengsheng submits application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on January 13th, Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. ("Shanghai Shengsheng") has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC and Sinolink (Hong Kong) acting as its joint sponsors. According to the prospectus, Shanghai Shengsheng is a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry in China. The company focuses on clinical trial temperature-controlled supply chain services, extends to commercial stage medical product temperature-controlled supply chain services, and conducts research and manufacturing of temperature-controlled equipment and materials to build comprehensive temperature-controlled supply chain capabilities for the full lifecycle and all application scenarios. According to the report by Frost & Sullivan, based on revenue in 2024, Shanghai Shengsheng is the top-ranked pharmaceutical and life sciences temperature-controlled supply chain service provider in the Chinese market, and is the only Chinese company among the top ten clinical trial temperature-controlled supply chain service providers globally.